N/A
N=15
Biomarkers of Intestinal Mucosal Healing in Crohn's Disease (P08143)
Crohn Disease
Bottom Line
View on ClinicalTrials.gov: NCT01349920 ↗Enrolled (actual)
15
Serious AEs
4.4%
Results posted
Sep 2016
Primary outcome: Primary: Change From Baseline in the Crohn's Disease Endoscopic Index of Severity (CDEIS) Blinded Score at Week 6 — -4.8 Score on a scale
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Infliximab (Drug)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Merck Sharp & Dohme LLC
- Primary completion
- Sep 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in the Crohn's Disease Endoscopic Index of Severity (CDEIS) Blinded Score at Week 6 |
-4.8 | — |
| PRIMARY Change From Baseline in CDEIS Blinded Score at Week 22 |
-7.3 | — |
| PRIMARY Change From Baseline in Serum High Sensitivity C-reactive Protein (hsCRP) at Week 6 |
-38.1 | — |
| PRIMARY Change From Baseline in Serum hsCRP at Week 22 |
-28.0 | — |
| PRIMARY Change From Baseline in Stool Calprotectin at Week 6 |
231.1 | — |
| PRIMARY Change From Baseline in Stool Calprotectin at Week 22 |
98.3 | — |
| PRIMARY Change From Baseline in Serum Lipocalin-2 at Week 6 |
-103.7 | — |
| PRIMARY Change From Baseline in Serum Lipocalin-2 at Week 22 |
-104.6 | — |
| PRIMARY Change From Baseline in Regenerating Islet-Derived 3-Alpha (REG3-A) at Week 6 |
-20.7 | — |
| PRIMARY Change From Baseline in REG3-A at Week 22 |
-21.2 | — |
| PRIMARY Coefficient of Determination (R^2) For Predicting The Change From Baseline In Blinded CDEIS Score From The Changes From Baseline In Four Biomarkers At Weeks 6 and 22 |
0.920; 0.638 | 0.071 |
| SECONDARY Concordance Correlation Coefficient for Comparison of Repeat Baseline Measurements of Biochemical Biomarkers |
0.954; 0.974; 0.910; 0.792 | — |
| SECONDARY Concordance Correlation Coefficient for Comparison Between Central Endoscopic Evaluation and Site Endoscopic Evaluation |
0.662; 0.693; 0.743; 0.453; 0.937; 0.753 | — |
Summary
This study will evaluate biomarkers that reflect changes in gut mucosal status during therapy with infliximab and determine whether changes in the levels of the selected biomarkers can be used to predict endoscopically assessed gut mucosal status changes.
Eligibility Criteria
Inclusion Criteria
- Clinical diagnosis of Crohn's Disease (CD) of at least 6 weeks duration, or acute diagnosis of sufficiently severe CD warranting initiation of infliximab sooner than allowed by fecal calprotectin turnaround time
- History of colonic involvement verified by prior endoscopy or radiography
- Indicated for treatment with infliximab according to current best medical practice
- Body Mass Index (BMI) between 15 kg/m^2 and 35 kg/m^2
- Women of childbearing potential and non-vasectomized men agree to use medically-acceptable contraception
- Negative pregnancy test
- No signs or symptoms of active tuberculosis (TB) and has a negative TB test within 6 weeks of first study drug administration
Exclusion Criteria
- Pregnancy, intention to become pregnant, or breastfeeding
- Evidence of a colon unaffected by CD
- Indication for surgery
- Perianal disease likely to interfere with study participation
- Presence of a stoma or history of colectomy
- Symptomatic diarrhea unrelated to CD
- Strictures or evidence of bowel obstruction
- Presence of abscess unless completed definitive treatment can be documented one week prior to screening
- Presence of fistulas
- Contraindication to infliximab
- Intolerance to sedatives or other medications required for endoscopy
- Any prior use of anti-inflammatory biologic therapy
- Moderate or severe congestive heart failure
- History of demyelinating disease or symptoms suggestive of multiple sclerosis or optic neuritis
- Major surgery or donation/loss of at least one unit of blood within 4 weeks of screening
- Positive for hepatitis B surface antigen, hepatitis C antibodies, or Human Immunodeficiency Virus (HIV)
- History of any tumor except adequately treated basal cell carcinoma or carcinoma in situ of the cervix
- History of systemic granulomatous infection
- History of nontuberculous mycobacterial disease, or any opportunistic infection within 12 months of study entry
- Transplanted organ including bone marrow or hematopoietic stem cell-derived marrow
Data sourced from ClinicalTrials.gov (NCT01349920). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.